.jpeg)
2026-09-07 05:08:46
Vorasidenib is an oral targeted therapy for glioma, taken continuously until disease progression or unacceptable toxicity. This article covers its dosing principles, liver monitoring, missed dose handling, and discontinuation rules.
2026-09-07 04:57:52
FDA approved Zanvastro intrathecal injection in September 2026 as the first disease-modifying drug for Alexander disease. This article covers its ASO mechanism, all-age indication, clinical trial efficacy, and safety guidelines.
2026-09-04 07:06:06
Pirfenidone (Esbriet) is an oral antifibrotic drug for idiopathic pulmonary fibrosis (IPF). This article details its stepwise dosing schedule, the necessity of taking with food, missed dose rules, and strategies for managing photosensitivity and gastrointestinal side effects.
2026-09-04 06:41:27
Ruxolitinib Cream (Opzelura) is a topical JAK inhibitor for mild-to-moderate atopic dermatitis and vitiligo. This article details application methods, differences between indications, local precautions, side effects, and efficacy expectations.
2026-09-03 06:11:28
Bedaquiline (Sirturo) is used for drug-resistant tuberculosis. This article explains its drug interactions, focusing on CYP3A4 inducers/inhibitors and QT-prolonging agents, to ensure treatment safety.
2026-09-03 05:11:16
Learn about Acalabrutinib (Calquence) recommended dosage (100mg twice daily), continuous treatment approach for CLL, MCL and SLL, administration tips, and adverse reaction management.
2026-09-02 07:24:03
Epclusa (Sofosbuvir/Velpatasvir) is the first pan-genotypic direct-acting antiviral regimen for chronic hepatitis C. This article details its dual-target mechanism, comparison with other DAAs, Child-Pugh guided regimens, and special population strategies.
2026-09-02 07:16:43
Lao Biktarvy is a generic version of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) produced in Laos for HIV-1 infection. This article explains its bioequivalence, comparison with other regimens, treatment-naïve and switch strategies, drug interactions, and monitoring.
2026-09-02 05:52:04
Finerenone is a non-steroidal selective mineralocorticoid receptor antagonist for chronic kidney disease associated with type 2 diabetes and for heart failure with LVEF ≥40%, adding a third pathway alongside RAAS and SGLT2 inhibitors.
2026-09-01 04:42:07
Selpercatinib is an oral RET inhibitor for RET fusion–positive NSCLC, thyroid cancer and other solid tumors, and RET-mutant medullary thyroid cancer. Dosing is weight-based, and acid-reducing agents require attention.
2026-09-01 04:25:06
Enasidenib is an oral small-molecule inhibitor of mutant IDH2. By lowering the oncometabolite 2-hydroxyglutarate (2-HG) and promoting myeloid differentiation, it is used in relapsed or refractory AML with an IDH2 mutation.
2026-09-01 03:28:25
Alpelisib is an oral PI3Kα inhibitor marketed as Piqray with fulvestrant for PIK3CA-mutated HR+/HER2− advanced breast cancer, and as Vijoice for PIK3CA-related overgrowth spectrum (PROS).
